Learn more about whether BioMarin Pharmaceutical Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

It is a smart strategy to diversify your portfolio by investing in high-quality companies built on proven technologies.

An international joint research team, including scientists from Switzerland, has revealed the origin of human fingers through ...

The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred.

Explore CRISPR technology explained, gene editing science, DNA modification, and genetic engineering ethics—discover how ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

Genetic engineers can design and assemble sophisticated gene circuits to program cells with new functions, but important ...

Technology opens the door to more accurate preclinical testing, which could enable the development of safer and more effective therapies.

Jarome and his team found that aging disrupts K63 polyubiquitination in two distinct areas of the brain. In the hippocampus, ...

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

Recognized in the Biotechnology category of the 2025 Top Innovations contest, small Cas12l nucleases are versatile, ...

Pairwise has licensed its Fulcrum® gene editing platform to the International Rice Research Institute (IRRI), a non-profit agricultural research organization. The agreement will enable IRRI to apply ...